Genetics of familial and sporadic Alzheimer’s disease
Irene Piaceri¹, Benedetta Nacmias¹, Sandro Sorbi¹

¹Department of Neurological and Psychiatric Sciences, University of Florence and Centro di Ricerca, Trasferimento e Alta Formazione DENO THE, University of Florence, Largo Brambilla 3, 50134 Firenze

TABLE OF CONTENTS
1. Abstract
2. Introduction
3. Familial Alzheimer’s disease
   3.1. Amyloid precursor protein
   3.2. Presenilin genes
      3.2.1. Presenilin 1 gene
      3.2.2. Presenilin 2 gene
4. Sporadic Alzheimer’s disease
   4.1. Apolipoprotein E
   4.2. Susceptibility genes and Genome wide association studies
   4.3. Alzheimer’s disease and the genes involved in neurofibrillary tangles
5. Perspective
6. Acknowledgments
7. References

1. ABSTRACT

Alzheimer's disease (AD) is an age-related progressive neurodegenerative disorder. A majority of cases manifest as a late onset sporadic form but genetically the disease is divided into familial cases and sporadic cases. The familial form is due to mutations in three major genes [amyloid precursor protein (APP) gene, presenilin 1 (PSEN1) gene and presenilin 2 (PSEN2) gene]. In contrast, many genetic and environmental factors may contribute to determining the sporadic AD form. Despite many years of research and great progress in the knowledge of the molecular pathogenesis of AD, a full understanding of the etiology of the sporadic form is still not yet in reach. Genome-wide association studies (GWASs) revealed the genetic complexity of the disease and recent studies suggested that epigenetic mechanisms may play an essential role in disease development. This review provides an overview of all the milestones in AD genetic research, as well as the new and promising approach, in order to better understand the genetic profile for predicting the risk of AD.

2. INTRODUCTION

Alzheimer's disease (AD) is an age-related progressive neurodegenerative disorder characterized by cognitive impairment, a variety of neuropsychiatric symptoms and restriction in the activities of daily living. An expert panel estimated that 24 million people worldwide are affected by dementia, most suffering from AD, and predicted that this would increase by about 81 million by 2040 (1). The most common form of AD is late onset AD (LOAD) that is defined as AD with an age at onset later than 65 years, while early-onset AD (EOAD) accounts for approximately 1% to 6% of all cases and age at onset ranges roughly from 30 years to 65 years. Genetically, AD is usually divided into familial cases with Mendelian inheritance (Familial AD, FAD) and sporadic cases with no familial aggregation. Familial cases are predominantly early-onset (younger than 65 years, early-onset familial AD; EOFAD), but also late onset cases (LOFAD) has been described (2). More than 90% of AD patients appear to be sporadic and usually with a late onset age (older than 65 years, LOAD). FAD is usually due to
Genetics of Alzheimer’s disease

Table 1. Mutations in candidate genes linked to Familial Alzheimer’s disease

<table>
<thead>
<tr>
<th>Gene</th>
<th>Locus</th>
<th>Mutations N (%)</th>
<th>Families N (%)</th>
<th>Age at onset range years</th>
</tr>
</thead>
<tbody>
<tr>
<td>APP</td>
<td>21q21.3</td>
<td>52 (7.66)</td>
<td>89 (8.63)</td>
<td>39-67</td>
</tr>
<tr>
<td>PSEN1</td>
<td>14q24.3</td>
<td>185 (43.94)</td>
<td>405 (37.92)</td>
<td>28-79</td>
</tr>
<tr>
<td>PSEN2</td>
<td>1q31-q42</td>
<td>13 (3.11)</td>
<td>22 (2.13)</td>
<td>39-85</td>
</tr>
</tbody>
</table>

3. FAMILIAL ALZHEIMER'S DISEASE

FAD is diagnosed in families that have more than one member with AD (usually multiple affected persons in more than one generation), but it is clinically indistinguishable from the sporadic form. Only 5% of all AD cases can be considered familial with an autosomal dominant inheritance due to mutations in the APP, PSEN1 and PSEN2 genes, and although several hundred families carry one of the mutations in these genes, they account for less than 1% of all cases (2). The determination of the mutations responsible for the disease in these families is an important step to better understand the molecular pathogenesis of AD, along with the clinical implication.

The majority of presenilin mutations cause the increased production of amyloid beta protein (A-beta) 1-42, that is the main component of amyloid plaques deposited in brain tissue. Moreover, it has been demonstrated that the toxicity of beta-amloid is expressed before the formation of fibrils (5).

3.1. Amyloid precursor protein

The prediction of an AD gene on chromosome 21 was put forward in 1984 when Glenner and Wong reported the amino acid sequence of the main component of beta-amloid, which they termed “amyloid beta protein” (A-beta), based on their analysis of cerebrovascular amyloid derived from patients with Down’s syndrome (6). As predicted by Glenner, the peptide derived from a much larger APP encoding by a gene mapped to chromosome 21. The APP gene is composed of 18 exons, and by alternative splicing can give rise to 10 different isoforms consisting of 563 to 770 amino acid residues. APP 695 is the predominant form in the central nervous system; the others are also present in other tissues. This gene encodes a large integral membrane glycoprotein with a large extracellular domain, a short intracytoplasmic carboxyl terminal and a central part of the beta-amloid. Two predicted cleavages produce the A-beta peptide from APP. One occurs in the extracellular domain by two enzymes: beta-secretase (identified now as BACE1 or beta-site APP cleaving enzyme 1) and gamma-secretase (comprising four proteins, one of which is PSEN1) (amyloidogenic pathway). Moreover, another enzyme, alpha-secretase, cleaves APP within the A-beta peptide and prevents the formation of A-beta; this is known as the “non-amyloidogenic pathway” (7,8). The processing of APP by alpha-secretase and gamma-secretase produces the formation of a short beta-amloid (A-beta 1-40) fragment that is not neurotoxic. In contrast, beta-secretase activity followed by gamma-secretase cleavage produces a different A-beta fragment, called A-beta 1-42. This fragment has been shown to be a more neurotoxic form due to its propensity to rapidly aggregate (8). The first mutation, also known as the London mutation, that causes EOFAD was identified in this gene (9) in exon 17, leading to a valine-to-isoleucine change at amino acid 717 (Val717Ile) (9). To date, over 30 different mutations in APP are currently listed in 89 families worldwide, including non-pathogenic ones (AD mutation database; http://www.molgen.ua.ac.be/ADMutations/). Interestingly, most of these mutations are located in exons 16 and 17, near the alpha-secretase cleavage site, in the central part of the beta-amloid peptide or near the gamma-secretase site of attack, giving rise to an increase or alteration in A-beta production (fragment A-beta 1-42) (10). Mutations in the APP gene are responsible for only a small percentage of all familial cases, about 9% (AD mutation database; http://www.molgen.ua.ac.be/ADMutations/; Table 1). All APP mutations are autosomal dominant and cause the disease with complete penetrance; however, in 2009, Di Fede and colleagues described a recessive APP mutation (A673V) with a dominant-negative effect on amyloidogenesis (11).

3.2. Presenilin genes

Linkage analysis and positional cloning studies have identified a family of two homologous genes that are known as presenilins (PSEN1 and PSEN2) and are involved in the majority of FAD cases (12,13,14). The structure of the two genes is very similar and they encode for two proteins that have high homology, around 67%. PSEN1 and PSEN2 are important determinants of gamma-secretase activity responsible for proteolytic cleavage of APP and NOTCH receptor proteins (15). Most of presenilin mutations lead to increased production of A-beta 1-42, altering the ratio of A-beta 1-42 to A-beta 1-40. It has been suggested that the toxicity of A-beta is expressed before the formation of fibrils resulting in a possible early preclinical event in presenilin mutation carriers (2). Most of PSEN1 and PSEN2 mutations are missense mutations causing amino acid substitution in proteins and, like APP mutations, are autosomal dominant.

3.2.1. Presenilin 1 gene

The PSEN1 gene is located on chromosome 14 (locus 14q24.3) and encodes a 467-amino acid
transmembrane protein that forms the catalytic core of the gamma-secretase complex. The first mutation identified in the PSEN1 gene as determinant for autosomal dominant EOFAD was reported in 1995 (13). To date, 185 pathogenic PSEN1 mutations have been identified in 405 AD families, making PSEN1 mutations the most common known genetic cause of EOFAD, although mutation frequency is highly dependent on the population studied (http://www.molgen.ua.ac.be/ADMutations) (Table 1). PSEN1 mutations cause the most severe forms of the disease, with an earlier age of onset and a considerable phenotypic variability (16). They are characterized by relatively rapid progression of the disease that is also often associated with seizures, myoclonus and language deficits. However, some of the clinical phenotypes have been associated with specific mutations, although most of them do not strongly depend on the genetic location of the mutation so other genetic or epigenetic factors may be involved (17). The median age of onset of the disease in families carrying PSEN1 mutations is about 45 years with a range of 28-79 years (18), correlated with the position of the mutation in a particular region of the gene. Several mutations associated with very early onset of cognitive decline are located within transmembrane domains and Miklossy et al. hypothesized that these substitutions may drastically alter the protein conformation (19). PSEN1 mutations penetrance is complete, but there are some exceptions that may be due to many factors which contribute to reduced penetrance (16).

3.2.2. Presenilin 2 gene

The PSEN2 gene is located on chromosome 1 (locus 1q31-q42) and encodes a 448-amino acid peptide with tissue-specific alternative splicing. Like PSEN1, PSEN2 is a transmembrane protein that is a part of the gamma-secretase responsible for the cleavage of A-beta. The first PSEN2 mutation was identified in 1995 in a collection of FAD pedigrees having a common ethnic background (Volga German) (12). To date, 20 mutations in PSEN2 have been identified in 22 families (http://www.molgen.ua.ac.be/ADMutations), making this gene a rare cause of FAD (Table 1). However, the pathogenicity is well documented in only thirteen identified mutations. For the others, it remains unclear (http://www.molgen.ua.ac.be/ADMutations).

The first mutation identified was the missense mutation and it resulted in the substitution of an isoleucine for an asparagine at residues 141 (N141I). The clinical phenotype associated with this mutation is the best characterized to date. The mean age of onset associated with N141I is 53.7 (range 39 to 75 years) with a disease duration of about ten years. The first symptoms were problems with memory, thinking or orientation and the disease was slow and progressive (20). However, the clinical features of PSEN2-affected families appear to differ from the clinical features of PSEN1-affected families. PSEN2 families show a wide range in age of onset (39-85 years) and the age of onset is highly variable among PSEN2-affected members of the same family, which may be due to the influence of other genetic or environmental factors (Table 1) (20).

4. SPORADIC ALZHEIMER’S DISEASE

About 95% of all cases of AD are considered sporadic forms of the disease. Over 60% of all sporadic cases are not associated with APOE, suggesting that other genetic and environmental factors may contribute to determining the disease.

4.1. Apolipoprotein E

The best-documented susceptibility gene for the development of AD is the APOE gene. This gene encodes for a 299-aminoacid lipoprotein binding amyloid proteins. Specifically, APOE exists in three common polymorphic forms (epsilon2, epsilon3 and epsilon4; rs429358) and one of them (epsilon4) is strongly associated with an increased risk of AD, not only in a homozygous state, but also in a heterozygous one. In contrast, the epsilon2 allele is associated with decreased risk. APOE is the main apolipoprotein in the brain that plays an important role in cholesterol homeostasis. The role of APOE in the predisposition to AD is well established (one copy of the epsilon 4 allele increases the risk by about 3-fold, two copies by about 12-fold), but the mechanism by which APOE is involved in the pathogenesis of AD is still not clear (21). One of the suggested mechanisms is linked to the ability of APOE to bind beta-amyloid, playing a role in A-beta conversion from monomeric and non-toxic forms to oligomers and fibrils. This is confirmed by the presence of APOE in both senile plaques and intracellular neurofibrillary tangles (NFTs), two important hallmarks of AD (22). Another possible mechanism may be due to the neurotoxic effects of APOE isoforms, independently of the interaction with beta-amyloid. The differences in amino acid in the three common isoforms alter the protein structure and influence the functional properties, including lipid regulation. APOE isoforms could have different effects via lipoprotein receptors leading to alternative neuronal signaling in the nervous system. Abnormal cholesterol metabolism contributes to impaired redistribution of lipids and cholesterol, which may affect neuronal plasticity (23). It is still unclear whether lipid dysregulation contributes to cerebral hypometabolism or whether the hypometabolism is secondary to altered A-beta metabolism or brain injury. Indeed, the regions typically involved in A-beta plaque deposition in AD patients coincide in normal brain with the regions that metabolize glucose by aerobic glycolysis. This is confirmed in subjects carrying the APOE epsilon4 allele who showed, through PET (Positron Emission Tomography) studies, reduced cerebral glucose metabolism (24) 20 years before disease onset. To date, APOE has been considered only an important risk factor for AD, but recently a multicenter study (17,000 subjects) demonstrating that the APOE risk is more similar to those of major genes in Mendelian diseases, urging a reappraisal of the impact of APOE in AD (25).

4.2. Susceptibility genes and Genome-wide association studies

In the past decade, a lot of candidate genes and regions emerging from genetic linkage and smaller scale association studies have been identified, but have often
Genetics of Alzheimer’s disease

Table 2. Main genetic variants identified by GWAS

<table>
<thead>
<tr>
<th>Gene</th>
<th>Locus</th>
<th>Polymorphism</th>
<th>Ethnicity</th>
<th>OR (95% CI)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOE</td>
<td>19q13</td>
<td>rs493358</td>
<td>All</td>
<td>0.879 (0.86-0.9)</td>
<td>3.37E-23</td>
</tr>
<tr>
<td>BIN1</td>
<td>2q14</td>
<td>rs394327</td>
<td>All</td>
<td>1.166 (1.1-1.2)</td>
<td>1.59E-26</td>
</tr>
<tr>
<td>CLU</td>
<td>8q21.1</td>
<td>rs11136000</td>
<td>Caucasian</td>
<td>3.879 (3.30-4.12)</td>
<td>7.85E-10</td>
</tr>
<tr>
<td>ABCA7</td>
<td>19p13.3</td>
<td>rs764650</td>
<td>All</td>
<td>1.229 (1.18-1.28)</td>
<td>8.17E-22</td>
</tr>
<tr>
<td>CR1</td>
<td>1q22</td>
<td>rs3818361</td>
<td>Caucasian</td>
<td>1.174 (1.14-1.21)</td>
<td>4.72E-21</td>
</tr>
<tr>
<td>PICALM</td>
<td>11q14</td>
<td>rs3851179</td>
<td>Caucasian</td>
<td>0.897 (0.86-0.91)</td>
<td>2.95E-20</td>
</tr>
<tr>
<td>CD33</td>
<td>1q21.3</td>
<td>rs3865444</td>
<td>All</td>
<td>0.893 (0.86-0.93)</td>
<td>2.04E-10</td>
</tr>
<tr>
<td>CD2AP</td>
<td>6p12</td>
<td>rs9349407</td>
<td>All</td>
<td>1.117 (1.08-1.16)</td>
<td>2.75E-09</td>
</tr>
<tr>
<td>EPHA1</td>
<td>7q34</td>
<td>rs1767557</td>
<td>All</td>
<td>0.90 (0.86-0.93)</td>
<td>6.0E-10</td>
</tr>
</tbody>
</table>

* according to the AlzGene database

proven difficult to replicate consistently. The emerging robust genome-wide association methodologies promises to explain the genetic etiology of the common sporadic forms of complex diseases such as AD (26). Despite numerous years of research, only one common genetic variant (the epsilon4 allele) of APOE has been considered a risk factor for LOAD. It has become clear that the majority of common genetic variants contribute only slightly to an increased risk for the disease, but in combination they have an important impact on disease predisposition. In the last four years, 22 published GWASs in AD have discovered additional candidate genes (http://www.alzgene.org) (27-48). Despite this exciting potential, GWAS results are not homogeneous and need further confirmation, and it is unclear whether GWASs can help explain most of the underlying genetic risk for AD. In 2007, the first published LOAD GWAS identified 16 different genetic loci associated with AD, using a selected set of 17,343 single nucleotide polymorphisms (SNPs) from 11,211 genes (33). To date, more than 50 SNPs have been identified. None of the identified loci showed the same consistent effect or the same level of statistical significance as the APOE epsilon4 allele. The polymorphisms consistently associated with AD risk across the different samples were located in close proximity to APOE, and most likely reflect linkage disequilibrium (LD) with the epsilon 4 allele. This is the case of a set of polymorphisms in Translocase of the Outer Mitochondrial Membrane 40 (TOMM40) gene recently identified in association with LOAD in independent genome-wide studies (27,34). The TOMM40 gene encoding an essential mitochondrial protein is located on chromosome 19, near the APOE locus, and it shows an intriguing LD with the epsilon4 allele. Furthermore, when all the SNPs were entered into a logit model, only the effect of APOE epsilon4 remained significant. These observations jeopardize the possibility that the loci in the TOMM40 gene may contribute to the risk for developing AD independently of APOE status (49).

The most important loci associated with LOAD identified by different GWA studies are located in 8 genes involved in new pathways (with considerable overlap shown by some genes) of the disease process which do not directly link to amyloid (50): CLU (clusterin, chr 8), PICALM (phosphatidylinositol binding clathrin assembly protein, chr 11), CR1 (complement component [3b/4b] receptor 1, chr 1) (34,38), BIN1 (bridging integrator 1, chr 2), ABCA7 (ATP-binding cassette transporter member 7, chr 19), CD33 (sialic acid binding Ig-like lectin 3, chr 19), EPHA1 (ephrin type-A receptor 1 chr 7) and CD2AP (CD2-associated protein chr 6) (36,40) (Table 2; Figure 1.). The

Table 2. Main genetic variants identified by GWAS

<table>
<thead>
<tr>
<th>Gene</th>
<th>Locus</th>
<th>Polymorphism</th>
<th>Ethnicity</th>
<th>OR (95% CI)</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>APOE</td>
<td>19q13</td>
<td>rs493358</td>
<td>All</td>
<td>0.879 (0.86-0.9)</td>
<td>3.37E-23</td>
</tr>
<tr>
<td>BIN1</td>
<td>2q14</td>
<td>rs394327</td>
<td>All</td>
<td>1.166 (1.1-1.2)</td>
<td>1.59E-26</td>
</tr>
<tr>
<td>CLU</td>
<td>8q21.1</td>
<td>rs11136000</td>
<td>Caucasian</td>
<td>3.879 (3.30-4.12)</td>
<td>7.85E-10</td>
</tr>
<tr>
<td>ABCA7</td>
<td>19p13.3</td>
<td>rs764650</td>
<td>All</td>
<td>1.229 (1.18-1.28)</td>
<td>8.17E-22</td>
</tr>
<tr>
<td>CR1</td>
<td>1q22</td>
<td>rs3818361</td>
<td>Caucasian</td>
<td>1.174 (1.14-1.21)</td>
<td>4.72E-21</td>
</tr>
<tr>
<td>PICALM</td>
<td>11q14</td>
<td>rs3851179</td>
<td>Caucasian</td>
<td>0.897 (0.86-0.91)</td>
<td>2.95E-20</td>
</tr>
<tr>
<td>CD33</td>
<td>1q21.3</td>
<td>rs3865444</td>
<td>All</td>
<td>0.893 (0.86-0.93)</td>
<td>2.04E-10</td>
</tr>
<tr>
<td>CD2AP</td>
<td>6p12</td>
<td>rs9349407</td>
<td>All</td>
<td>1.117 (1.08-1.16)</td>
<td>2.75E-09</td>
</tr>
<tr>
<td>EPHA1</td>
<td>7q34</td>
<td>rs1767557</td>
<td>All</td>
<td>0.90 (0.86-0.93)</td>
<td>6.0E-10</td>
</tr>
</tbody>
</table>

* according to the AlzGene database

The most important loci associated with LOAD identified by different GWA studies are located in 8 genes involved in new pathways (with considerable overlap shown by some genes) of the disease process which do not directly link to amyloid (50): CLU (clusterin, chr 8), PICALM (phosphatidylinositol binding clathrin assembly protein, chr 11), CR1 (complement component [3b/4b] receptor 1, chr 1) (34,38), BIN1 (bridging integrator 1, chr 2), ABCA7 (ATP-binding cassette transporter member 7, chr 19), CD33 (sialic acid binding Ig-like lectin 3, chr 19), EPHA1 (ephrin type-A receptor 1 chr 7) and CD2AP (CD2-associated protein chr 6) (36,40) (Table 2; Figure 1.). The clusterin protein encoding by the CLU gene, also known as apolipoprotein J (APOJ), has been observed in amyloid deposits (A-beta is one of its ligands) (51), and its levels seem to be increased in AD patients’ cerebrospinal fluid (52), supporting the observed genetic association. The clearance of A-beta can be mediated by CLU enhancing endocytosis (53) and/or through transport across the blood–brain barrier (54). The PICALM gene encodes the ubiquitous protein involved in clathrin-mediated endocytosis (CME) (55) which is an essential step in intracellular trafficking of proteins, lipids, growth factors and neurotransmitters. Moreover, it is indispensable for neurotransmitter release at the presynaptic membrane, which is important for memory formation and neuronal function, and it may play a role in A-beta clearance from the brain (56). The significant association reported for the 5’end in PICALM rs3851179 is a reduced risk for LOAD (34). In addition to PICALM, it has been suggested that CR1 also provides a protective role in AD, through the binding of C3b and subsequent A-beta clearance (38). CR1 encodes a complement receptor type 1 that plays an important role in the regulation of the complement cascade and the clearance of immune complexes (57). Although the functional relevance of the polymorphism in CR1 for LOAD is still unclear, it is conceivable that the genetic variation affects AD through neuroinflammation independently of its function in A-beta clearance. BIN1, as PICALM, is implicated in CME, which allows the internalization and transport of lipids, and is a critical component of synaptic vesicle recycling (58). BIN1 may influence the formation of the other main pathological features of AD brains, the NFTs, linking the microtubule cytoskeleton with the cellular membrane (59). ABCA7 encodes an ATP-binding cassette (ABC) transporter, which plays a role in transporting a wide range of substrates across cell membranes (60). It is highly expressed in brain, particularly in the hippocampal CA1 neurons and microglia (61,62). ABCA7 is involved in many pathways linked directly and indirectly with APP processing: efflux of lipids from cells to lipoprotein particles, regulation of APP processing and inhibition of beta-amyloid secretion (63). CD33 is a member of the sialic-acid-binding immunoglobulin-like lectins (Siglec) family and mediates endocytosis through a mechanism independent of clathrin (64). Moreover, it promotes cell-cell interactions and regulates the functions of cells in innate and adaptive immune systems (65). EPHA1 is a member of the ephrin receptor subfamily, which plays roles in cell and axon guidance and in synaptic development and plasticity (66,67). CD2AP is a scaffold adaptor protein that is associated with cortactin, a protein also involved in the...
regulation of receptor-mediated endocytosis (68), such as the previously described genes, PICALM, BIN1 and CD33. The described genes are involved in different pathways that highlight additional mechanisms associated with the disease process, and the result of these finding may make it possible to consider that A-beta may have a minor role in the LOAD pathogenesis.

4.3. Alzheimer’s disease and the genes involved in neurofibrillary tangles

In addition to extracellular beta-amyloid plaque, NFTs are another important hallmark of AD and the genes involved in their production may have a key role in the development of AD. The major component of NFTs is Tau, a microtubule-associated protein that is abnormally hyperphosphorilated and forms insoluble fibrils. Tau protein is encoded by the MAPT (Microtubule Association Protein Tau) gene, located on chromosome 17, and it is expressed predominantly in the neurons of the peripheral and central nervous system. Physiologically, the protein is a component of microtubules and it has a role in stabilizing the growing axons, neuronal polarity and signal transduction (1,69). The pathways linking Tau and A-beta are not clear, but Tau expression appears to be necessary for A-beta toxicity in ex vivo experiments (70). The toxic gain of function combined with the loss of function of normal Tau could compromise axonal transport and contribute to synaptic degeneration (71). The genetic link between MAPT and AD started with the identification of a strong association between AD and a Tau haplotype (H1c) (72). Since 2007, several studies have analyzed the MAPT gene in EOFAD patients as well, identifying two mutations (in particular, c.1920+16 C>T NM_001123066.3 and R406W) associated with an AD-like phenotype (73,74).

Moreover, a study in 2009 identified the MAPT deltaK280 mutation in a LOAD patient with no documentation of a family history (75). The pathological role of this mutation is not yet clear, but in light of these studies, screening of the MAPT gene should be considered in families with AD-like phenotype not carrying mutations in known AD genes. In AD brain, the distribution of Tau hyperphosphorilated within neurons with NFTs overlaps with the distribution of another protein, TDP-43 (Transactive response DNA-binding protein 43), encoded by the TARDBP gene on chromosome 1. This is a nuclear protein involved in several neurodegenerative diseases (76). TDP-43 inclusion is detected in approximately 25-30% of sporadic AD, raising the hypothesis that TARDBP mutations or SNPs may be involved in AD pathogenesis. To date, screening of this gene in AD patients showed conflicting results (76,77,78). Only a rare mutation in exon 3 (p.Ala90Val) of an unclear pathogenic nature was identified in three different patients sharing a common founder (77). These results suggest that TARBDP mutations or SNPs are not a significant cause of AD; however, other studies will be necessary to better understand the genetic role of TARDBP in AD pathogenesis. After many years of research studying the involvement of genetics in AD, one of the most controversial research fields is still the identification of AD genes possibly implicated in NFTs. Indeed, the presence of NFTs is just the final pathway of a slow neuronal degeneration, thus it is important to study not only the genes involved in fibril formation or structure, but also the genes involved in all the molecular and cellular mechanisms resulting in NFTs. In fact, it was hypothesized that the imbalance between phosphorylation (by kinases) and de-phosphorylation (by phosphatases) may play a major role in the development of the tau pathology. Thus,
Genetics of Alzheimer’s disease

the identification of the kinases or phosphatases responsible in tau phosphorylation is a crucial issue; still very important is the identification of all genetic or epigenetic mechanisms possibly influencing their function.

5. PERSPECTIVES

To date, all of the described genetic factors do not completely explain the pathophysiology of AD: indeed, studies on the possible risk factors for the sporadic forms often appear to be conflicting, not replicable or inconclusive. The gene-environment interaction plays an important role in the majority of sporadic AD cases. Epigenetic studies provide the tools for understanding the interaction between genes and environmental factors and thus represent the new frontier for gaining insight into the genetics of AD (79). Recent studies have suggested that epigenetic mechanisms may play an essential role in the disease development. It is clear that epigenetic dysregulation at various levels is associated with the disease and it mediates the AD risk. Nonetheless, it is not yet fully understood whether epigenetic changes are a cause or a consequence of the disease. In fact, to date, only a few studies have been carried out and have primarily analyzed samples of patients already in the advanced stage of the disease. In order to clarify the importance of the epigenetic mechanism and the dynamics of DNA methylation, further prospective investigations will be necessary (80) on both the early-stages and the advanced phases of AD. In conclusion, the genetic component of some cases of dementia has long been recognized (81), with the identification of the first locus on chromosome 21. At the beginning, the low incidence of these cases in the overall demented population has lead clinicians working on dementia to consider the genetic component to be of little practical relevance. Despite many years of research and great progress in the knowledge of the molecular pathogenesis of AD, a full understanding of the etiology of the sporadic form is still out of reach. However, new discoveries found by GWASs could characterize an important proportion of the genetic architecture contributing to the development of the disease. After almost 25 years (81), important results have been obtained with genetic studies. Indeed, since the first pathogenetic mutation was identified in 1991 (9), the description of over 220 different mutations and the identification of new susceptibility genes has kindled new interest. To date, although its utility in clinical practice is still often unclear, the genetic approach deserves critical discussion and provides ample stimulus for further research.

6. ACKNOWLEDGMENTS

This study was supported by Grants from the Cassa di Risparmio di Firenze 2010 and the Ministry of Health 2010 convenzione 39 sottoprogetto 2.

7. REFERENCES


Genetics of Alzheimer’s disease


Genetics of Alzheimer’s disease


Genetics of Alzheimer’s disease


Genetics of Alzheimer's disease


**Abbreviations:** AD: Alzheimer's disease; FAD: Familial Alzheimer's disease; EOFAD: Early-onset familial Alzheimer's disease; LOAD: Late-onset Alzheimer's disease; APP: amyloid precursor protein; PSEN1: presenilin 1; PSEN2: presenilin 2; APOE: Apolipoprotein E; A-beta: amyloid beta protein; BACE1: beta -site APP cleaving enzyme 1; GWASs: Genome-wide association studies; NFTs: neurofibrillary tangles; PET: Positron Emission Tomography; SNPs: Single Nucleotide polymorphisms; LD: linkage disequilibrium; TOMM40: Translocase of the Outer Mitochondrial Membrane 40; CLU: clusterin; PICALM: phosphatidylinositol binding clathrin assembly protein; CR1: complement component [3b/4b] receptor 1; BIN1: bridging integrator 1; ABCA7: ATP-binding cassette transporter member 7; CD33: sialic acid binding Ig-like lectin 3; EPHA1: ephrin type-A receptor 1; CD2AP: CD2-associated protein; APOJ: apolipoprotein J; CME: clathrin-mediated endocytosis; H1c: tau haplotype; MAPT: Microtubule Association Protein Tau; TDP-43: Transactive response DNA-binding protein 43; SIRT1: sirtuin 1; RARalpha: retinoic acid receptor-alpha

**Key Words:** Alzheimer’s disease, Genes Mutation, Single Nucleotide Polymorphisms, Epigenetics, GWAS, Review

**Send correspondence to:** Benedetta Nacmias, Department of Neurological and Psychiatric sciences, University of Florence, Largo Brambilla 3, 50134 Florence, Italy, Tel: 390554271379, Fax: 390554271380, E-mail: nacmias@unifi.it